NCT07376629 2026-01-29A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCHuabo Biopharm Co., Ltd.Phase 2 Enrolling by invitation60 enrolled
NCT05918133 2025-03-11A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCBiotheus Inc.Phase 1/2 Active not recruiting42 enrolled